17077358

Source:http://linkedlifedata.com/resource/pubmed/id/17077358

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003241, umls-concept:C0301630, umls-concept:C1140680, umls-concept:C1280500, umls-concept:C1333337
pubmed:issue	21
pubmed:dateCreated	2006-11-1
pubmed:abstractText	EphA2 is an oncoprotein and tyrosine kinase receptor that is overexpressed in ovarian and many other cancers. We investigated the effects of reduced EphA2 levels on tumor growth and the tumor microenvironment in an orthotopic ovarian cancer model.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/2P50CA083639
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503089
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, EphA2, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1460-2105
pubmed:author	pubmed-author:BruckheimerElizabethE, pubmed-author:CoffmanKaren TKT, pubmed-author:GallickGary EGE, pubmed-author:GaoChanghouC, pubmed-author:GershensonDavid MDM, pubmed-author:HalderJyotsnabaranJ, pubmed-author:HanLiz YLY, pubmed-author:KamatAparna AAA, pubmed-author:KinchMichael SMS, pubmed-author:LandenCharles NCNJr, pubmed-author:LinYvonne GYG, pubmed-author:LuChunhuaC, pubmed-author:MangalaLingegowda SLS, pubmed-author:MerrittWilliam MWM, pubmed-author:ParikhNila UNU, pubmed-author:SchmandtRosemarieR, pubmed-author:SoodAnil KAK, pubmed-author:ThakerPremalP, pubmed-author:YangLiL
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	98
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1558-70
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:17077358-Analysis of Variance, pubmed-meshheading:17077358-Angiogenesis Inhibitors, pubmed-meshheading:17077358-Animals, pubmed-meshheading:17077358-Antibodies, Monoclonal, pubmed-meshheading:17077358-Antineoplastic Agents, pubmed-meshheading:17077358-Cell Line, Tumor, pubmed-meshheading:17077358-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:17077358-Female, pubmed-meshheading:17077358-Humans, pubmed-meshheading:17077358-Immunoblotting, pubmed-meshheading:17077358-Immunohistochemistry, pubmed-meshheading:17077358-Immunoprecipitation, pubmed-meshheading:17077358-In Situ Hybridization, pubmed-meshheading:17077358-In Situ Nick-End Labeling, pubmed-meshheading:17077358-Mice, pubmed-meshheading:17077358-Neovascularization, Pathologic, pubmed-meshheading:17077358-Ovarian Neoplasms, pubmed-meshheading:17077358-Receptor, EphA2, pubmed-meshheading:17077358-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17077358-Vascular Endothelial Growth Factor A
pubmed:year	2006
pubmed:articleTitle	Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
pubmed:affiliation	Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
pubmed:publicationType	Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural